{
    "clinical_study": {
        "@rank": "80754", 
        "acronym": "COGNIS", 
        "arm_group": [
            {
                "arm_group_label": "New infant formula", 
                "arm_group_type": "Experimental", 
                "description": "New infant formula with key ingredients."
            }, 
            {
                "arm_group_label": "Standard infant formula", 
                "arm_group_type": "Active Comparator", 
                "description": "Standard infant formula"
            }
        ], 
        "brief_summary": {
            "textblock": "To compare the neurocognitive and immunological development in infants fed a new infant\n      formula with functional specific nutrients to infants consuming a standard infant formula."
        }, 
        "brief_title": "A Neurocognitive and Immunological Study of a New Formula for Healthy Infants", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Infant Development", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Full-term newborns (>37 weeks and <41 weeks gestation)\n\n          -  Adequate birth weight for his gestational age (between 3-97 percentiles)\n\n          -  Inclusion age: from 0 to 2 months (60 days)\n\n          -  Maximum 30 days of exclusive breastfeeding\n\n          -  From 30 days on, exclusive or >70% infant formula\n\n          -  Normal Apgar score: 7-10\n\n          -  Umbilical pH \u2265 of 7.10\n\n          -  Availability to continue during the whole study period\n\n          -  Informed consent signed ( parent/legal representative)\n\n        Exclusion Criteria:\n\n          -  Participating in other studies.\n\n          -  Nervous system disorders (hydrocephalic, perinatal hypoxia, intraventricular\n             hemorrhage, neonatal meningitis, septic shock, West Sd...).\n\n          -  Gastrointestinal disorders (cow's milk protein allergy, lactose intolerance)\n\n          -  Mother's disease history or during pregnancy: neurological and metabolic diseases,\n             diabetes mellitus type 1, hypothyroidism, undernutrition, infections TORCH complex.\n\n          -  Mothers receiving anxiolytic or antidepressant treatment during pregnancy or other\n             potentially harmful drug treatments for infants' neurodevelopment.\n\n          -  Infant currently participating in another clinical study\n\n          -  Infant's family who in the investigators assessment cannot be expected to comply with\n             the protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Days", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "170", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02094547", 
            "org_study_id": "FC0G - 010"
        }, 
        "intervention": [
            {
                "arm_group_label": "New infant formula", 
                "description": "New infant formula", 
                "intervention_name": "New infant formula", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Standard infant formula", 
                "description": "Standard infant formula", 
                "intervention_name": "Standard infant formula", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Infant Formula", 
            "Cognition", 
            "Neurodevelopment", 
            "Immunity", 
            "Microbiota"
        ], 
        "lastchanged_date": "March 21, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Granada", 
                    "country": "Spain", 
                    "zip": "18071"
                }, 
                "name": "Facultad de Medicina"
            }
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Evaluaci\u00f3n Del Efecto de Una Nueva f\u00f3rmula Infantil Con Ingredientes espec\u00edficos Sobre el Desarrollo Neurocognitivo e inmunol\u00f3gico en Lactantes", 
        "other_outcome": {
            "description": "Food frequency questionnaires and 24 h food recalls.", 
            "measure": "Dietary assessment", 
            "safety_issue": "No", 
            "time_frame": "At 6th, 12th and 18th months"
        }, 
        "overall_official": {
            "affiliation": "Universidad de Granada", 
            "last_name": "Cristina Campoy, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Spain: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Differences in neurocognitive development inter and intragroup evaluated by visual evoked potential test, general movements test, BAYLEY'S III test, Hempel test and cognitive evoked potential test (EEG/ERP).", 
            "measure": "Neurocognitive Development", 
            "safety_issue": "No", 
            "time_frame": "At 2nd, 3rd, 4th, 6th, 12th and 18th months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02094547"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Evaluation of gastrointestinal symptoms and sleep disorders amongst groups.", 
                "measure": "Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "At 2nd, 3rd, 4th, 6th, 12th and 18th months"
            }, 
            {
                "description": "Differences in growth parameters (weight, length, BMI, skin folds, perimeters and z-scores) between groups.", 
                "measure": "Growth", 
                "safety_issue": "No", 
                "time_frame": "At 2nd, 3rd, 4th, 6th, 12th and 18th months"
            }, 
            {
                "description": "Number of infections reported.", 
                "measure": "Incidence of infections", 
                "safety_issue": "No", 
                "time_frame": "At 2nd, 3rd, 4th, 6th, 12th and 18th months"
            }, 
            {
                "description": "Inter and intragroup differences measured by saliva samples analysis.", 
                "measure": "Immunoglobulin A secretor (IgAs) levels", 
                "safety_issue": "No", 
                "time_frame": "At 3rd, 6th, 12th and 18th months"
            }, 
            {
                "description": "Changes in microbiota composition measured by real-time polymerase chain reaction (RT-PCR) in faeces.", 
                "measure": "Impact on microbiota", 
                "safety_issue": "No", 
                "time_frame": "At 3rd, 6th, 12th and 18th months"
            }, 
            {
                "description": "Differences in LC-PUFAS levels inter and intragroup evaluated by oral mucosa samples analysis.", 
                "measure": "Long Chain Polyunsaturated Fatty Acids (LC-PUFAS) levels", 
                "safety_issue": "No", 
                "time_frame": "At 3rd, 6th, 12th and 18th months"
            }
        ], 
        "source": "Laboratorios Ordesa", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Laboratorios Ordesa", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}